US Patent 9758578 Human anti-IL-33 neutralizing monoclonal antibody
Patent 9758578 was granted and assigned to Mitsubishi Tanabe Pharma on September, 2017 by the United States Patent and Trademark Office.
All edits
An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.
US Patent 09758578 Human anti-IL-33 neutralizing monoclonal antibody US Patent 9758578 Human anti-IL-33 neutralizing monoclonal antibody
US Patent 09758578 Human anti-IL-33 neutralizing monoclonal antibody
Find more entities like US Patent 9758578 Human anti-IL-33 neutralizing monoclonal antibody
